B-Cell Depletion in Glomerular Diseases: Not Always as Safe as We May Think
B-cell depletion with the chimeric anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of glomerular diseases. Obinutuzumab, a type II glycoengineered anti-CD20 humanized monoclonal antibody, is increasingly being employed as an alternative to rituximab in the management of diff...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Elsevier
2026-03-01
|
| Schriftenreihe: | Kidney Medicine |
| Schlagworte: | |
| Online-Zugang: | http://www.sciencedirect.com/science/article/pii/S2590059526000294 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|